Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Deals·AgileMD

Wolters Kluwer bets up to $100 million that UpToDate belongs inside the EHR

Wolters Kluwer Health will pay $40 million upfront for AgileMD, a 23-person San Francisco company that sells clinical pathways and an FDA-cleared deterioration alert, with up to $60 million more tied to performance.

From Wolters Kluwer and AgileMD announcements published Nov. 13, 2026, HIT Consultant coverage published Nov. 13, and FDA 510(k) records
A nurse at a mobile computer workstation in a hallway at Virginia Mason Hospital in Seattle in 2010.
A nurse at a mobile computer workstation in a hallway at Virginia Mason Hospital in Seattle in 2010. File photo.Wonderlane / Wikimedia Commons (CC BY 2.0)
Value
$100M
Type
Acquisition
Target
AgileMD
Buyer
Wolters Kluwer Health
Sector
Health AI
Announced
Nov. 13, 2026

Wolters Kluwer says its UpToDate Expert AI tool is already in use at more than 2,700 U.S. hospitals and health systems. Now it is paying for a way to build that content into the electronic health record itself.

Wolters Kluwer Health said Nov. 13 that it agreed to acquire AgileMD, a San Francisco clinical decision support company, for up to $100 million. Wolters Kluwer will pay $40 million upfront, with the balance deferred and tied to performance targets, according to its announcement. HIT Consultant reported the deferred portion at up to $60 million.

Why it matters: The deal gives Wolters Kluwer software that already runs inside EHR workflows, the place it says it wants UpToDate to reach. Measured against AgileMD's revenue, the upfront payment is about 5.7 times the $7 million in annual recurring revenue Wolters Kluwer expects AgileMD to reach by the end of 2026, and the full $100 million is about 14 times.

What AgileMD sells

AgileMD, founded in 2011, sells two products named in the announcement. Pathways builds a hospital's local guidelines into the EHR workflow, which the company says supports consistent care and outcomes measurement. eCART is a real-time clinical surveillance engine that Wolters Kluwer describes as AI-powered; HIT Consultant reported that it predicts deterioration in hospitalized patients.

FDA records show AgileMD's eCARTv5 Clinical Deterioration Suite was cleared through the 510(k) pathway on June 21, 2024, under K233253.

The company is small. All 23 employees will join Wolters Kluwer Health, the announcement said. Borna Safabakhsh, a co-founder, is chief executive, and Dana Edelson, a physician and co-founder, is chief medical officer.

"We are excited to join Wolters Kluwer Health," Safabakhsh said.

The UpToDate angle

Wolters Kluwer framed the deal around UpToDate Expert AI, which it introduced in September 2025. The company said more than 2,700 U.S. hospitals and health systems have adopted it, or more than 95% of its U.S. UpToDate Enterprise Edition customers. Pairing it with AgileMD is meant to carry that content into embedded workflows and local guidelines, the company said.

"AgileMD will serve as a vital enabler for true UpToDate ubiquity in healthcare," said Yaw Fellin, senior vice president of Wolters Kluwer Clinical Solutions.

Wolters Kluwer is not the only company trying to get reference content closer to the point of care. Suki, which made its name turning doctor-patient conversations into notes, introduced a product called Ask in October that puts UpToDate Expert AI content inside clinicians' workflows, a week before it announced a $90 million Series E. Meanwhile, Vera Health raised $28.5 million for a free clinical evidence search tool it says more than 800,000 clinicians use.

What comes next

The acquisition is subject to customary closing conditions and other governmental approvals, and Wolters Kluwer expects it to close in the first quarter of 2027 or sooner. The company said it expects the deal to have an immaterial effect on adjusted earnings and to earn a return on invested capital at or above its 8% after-tax weighted average cost of capital within three to five years. The announcement did not spell out the performance targets that would trigger the deferred payments.

Sara Montes de Oca is the Editor in Chief of Charted. She previously worked as a correspondent and producer in Washington, D.C., covering business, finance, and politics. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Deals

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.